Artículos por temáticas

Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease

Heo JY, Nam MH, Yoon HH, Kim J, Hwang YJ, Won W, Woo DH, Lee JA, Park HJ, Jo S, Lee MJ, Kim S, Shim JE, Jang DP, Kim KI, Huh SH, Jeong JY, Kowall NW, Lee J, Im H, Park JH, Jang BK, Park KD, Lee HJ, Sh

Curr Biol. 2020 Jan 20;30(2):276-291.e9. doi: 10.1016/j.cub.2019.11.079. Epub 2020 Jan 9.

Parkinson's disease: From bench to bedside

Draoui A, El Hiba O, Aimrane A, El Khiat A, Gamrani H.

Rev Neurol (Paris). 2020 Sep;176(7-8):543-559. doi: 10.1016/j.neurol.2019.11.002. Epub 2020 Jan 9.

Current Status of Pain Management in Parkinson's Disease

Karnik V, Farcy N, Zamorano C, Bruno V.

Can J Neurol Sci. 2020 May;47(3):336-343. doi: 10.1017/cjn.2020.13.

Smartphone Based Timed Up and Go Test Can Identify Postural Instability in Parkinson's Disease

Yahalom G, Yekutieli Z, Israeli-Korn S, Elincx-Benizri S, Livneh V, Fay-Karmon T, Tchelet K, Rubel Y, Hassin-Baer S.

Isr Med Assoc J. 2020 Jan;22(1):37-42.

Non-motor Symptoms in Parkinson's Disease Patients with Parkin Mutations: More Depression and Less Executive Dysfunction

Song J, Shen B, Yang YJ, Liu FT, Zhao J, Tang YL, Chen C, Ding ZT, An Y, Wu JJ, Sun YM, Wang J.

J Mol Neurosci. 2020 Feb;70(2):246-253. doi: 10.1007/s12031-019-01444-3. Epub 2020 Jan 11.

Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson's disease and matched controls during daily living

Shah VV, McNames J, Mancini M, Carlson-Kuhta P, Spain RI, Nutt JG, El-Gohary M, Curtze C, Horak FB.

J Neurol. 2020 Apr;267(4):1188-1196. doi: 10.1007/s00415-020-09696-5. Epub 2020 Jan 11.

Up-regulation of microRNA-375 ameliorates the damage of dopaminergic neurons, reduces oxidative stress and inflammation in Parkinson's disease by inhibiting SP1

Cai LJ, Tu L, Li T, Yang XL, Ren YP, Gu R, Zhang Q, Yao H, Qu X, Wang Q, Tian JY.

Aging (Albany NY). 2020 Jan 11;12(1):672-689. doi: 10.18632/aging.102649. Epub 2020 Jan 11.

Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy

Hulme H, Fridjonsdottir E, Gunnarsdottir H, Vallianatou T, Zhang X, Wadensten H, Shariatgorji R, Nilsson A, Bezard E, Svenningsson P, Andrén PE.

Neurobiol Dis. 2020 Apr;137:104738. doi: 10.1016/j.nbd.2020.104738. Epub 2020 Jan 10.

Polydatin protects SH-SY5Y in models of Parkinson's disease by promoting Atg5-mediated but parkin-independent autophagy

Bai H, Ding Y, Li X, Kong D, Xin C, Yang X, Zhang C, Rong Z, Yao C, Lu S, Ji L, Li L, Huang W.

Neurochem Int. 2020 Mar;134:104671. doi: 10.1016/j.neuint.2020.104671. Epub 2020 Jan 8.

Ondansetron, a highly selective 5-HT(3) receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease

Kwan C, Frouni I, Bédard D, Hamadjida A, Huot P.

Eur J Pharmacol. 2020 Mar 15;871:172914. doi: 10.1016/j.ejphar.2020.172914. Epub 2020 Jan 8.

Correction to: A phase 2, open-label, multi-center study to evaluate the efficacy and safety of (99m)Tc-TRODAT-1 SPECT to detect Parkinson's disease

Sun Y, Liu C, Chen Z, Li B, Lv Z, Lou J, Tang J, Wang Y, Zhang G, Liu X.

Ann Nucl Med. 2020 Jan;34(1):38. doi: 10.1007/s12149-019-01434-w.

Alteration of brain temperature and systemic inflammation in Parkinson's disease

Chen HL, Yamada K, Sakai K, Lu CH, Chen MH, Lin WC.

Neurol Sci. 2020 May;41(5):1267-1276. doi: 10.1007/s10072-019-04217-3. Epub 2020 Jan 10.

Automatic detection and quantification of hand movements toward development of an objective assessment of tremor and bradykinesia in Parkinson's disease

Pang Y, Christenson J, Jiang F, Lei T, Rhoades R, Kern D, Thompson JA, Liu C.

J Neurosci Methods. 2020 Mar 1;333:108576. doi: 10.1016/j.jneumeth.2019.108576. Epub 2020 Jan 7.

Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S; COPARK Study Group.

Drugs Aging. 2020 Mar;37(3):215-223. doi: 10.1007/s40266-019-00740-2.

Clinical potential and current progress of mesenchymal stem cells for Parkinson's disease: a systematic review

Chen Y, Shen J, Ke K, Gu X.

Neurol Sci. 2020 May;41(5):1051-1061. doi: 10.1007/s10072-020-04240-9. Epub 2020 Jan 9.